{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:56Z","timestamp":1786982216702,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["150560\/2019-2"],"award-info":[{"award-number":["150560\/2019-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance code 001"],"award-info":[{"award-number":["Finance code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance code 001"],"award-info":[{"award-number":["Finance code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance code 001"],"award-info":[{"award-number":["Finance code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004263","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio Grande do Sul","doi-asserted-by":"publisher","award":["#16\/2551-0000526-5 (PRONUPEQ)"],"award-info":[{"award-number":["#16\/2551-0000526-5 (PRONUPEQ)"]}],"id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004263","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio Grande do Sul","doi-asserted-by":"publisher","award":["#16\/2251-0000183-9 (ARD\/PPP)."],"award-info":[{"award-number":["#16\/2251-0000183-9 (ARD\/PPP)."]}],"id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12035-020-01940-3","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T03:03:08Z","timestamp":1590462188000},"page":"3027-3041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Hesperidin Ameliorates Anxiety-Depressive-Like Behavior in 6-OHDA Model of Parkinson\u2019s Disease by Regulating Striatal Cytokine and Neurotrophic Factors Levels and Dopaminergic Innervation Loss in the Striatum of Mice"],"prefix":"10.1007","volume":"57","author":[{"given":"Michelle S.","family":"Antunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0973-1371","authenticated-orcid":false,"given":"Leandro","family":"Cattelan Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Vagner Lobo","family":"Ladd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliny Antunes Barbosa Lobo","family":"Ladd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Lopez","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandreza Cardoso","family":"Bortolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia R\u00f3sula Poetini","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00edfani Machado","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Prigol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Wayne","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana Peterini","family":"Boeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"key":"1940_CR1","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","volume":"373","author":"AJ Lees","year":"2009","unstructured":"Lees AJ, Hardy J, Revesz T (2009) Parkinson\u2019s disease. Lancet 373:2055\u20132066","journal-title":"Lancet"},{"key":"1940_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev-pathol-011110-130242","volume":"2011","author":"JM Shulman","year":"2011","unstructured":"Shulman JM, De Jager PL, Feany MB (2011) Parkinson's disease: Genetics and pathogenesis. Annu Rev Pathol 2011:193\u2013222","journal-title":"Annu Rev Pathol"},{"key":"1940_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.eurpsy.2006.01.012","volume":"21","author":"HM Wichowicz","year":"2006","unstructured":"Wichowicz HM, S\u0142awek J, Derejko M, Cuba\u0142a WJ (2006) Factors associated with depression in Parkinson\u2019s disease: a cross-sectional study in a Polish population. Eur Psychiatry 21:516\u2013520. https:\/\/doi.org\/10.1016\/j.eurpsy.2006.01.012","journal-title":"Eur Psychiatry"},{"key":"1940_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jad.2011.01.021","volume":"132","author":"NN Dissanayaka","year":"2011","unstructured":"Dissanayaka NN, Sellbach A, Silburn PA, O'Sullivan JD, Marsh R, Mellick GD (2011) Factors associated with depression in Parkinson's disease. J Affect Disord 132:82\u201388","journal-title":"J Affect Disord"},{"key":"1940_CR5","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson's disease. Lancet 386:896\u2013912","journal-title":"Lancet"},{"key":"1940_CR6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1517\/14728222.9.5.887","volume":"9","author":"JM Craft","year":"2005","unstructured":"Craft JM, Watterson DM, Van Eldik LJ (2005) Neuroinflammation: a potential therapeutic target. Expert Opin Ther Targets 9:887\u2013900","journal-title":"Expert Opin Ther Targets"},{"key":"1940_CR7","first-page":"23","volume":"10","author":"F Moosavi","year":"2015","unstructured":"Moosavi F, Hosseini R, Saso L, Firuzi O (2015) Modulation of neurotrophic signaling pathways by polyphenols. Drug Des Devel Ther 10:23\u201342","journal-title":"Drug Des Devel Ther"},{"key":"1940_CR8","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.1007\/s12035-016-0214-7","volume":"54","author":"S Pramanik","year":"2017","unstructured":"Pramanik S, Sulistio YA, Heese K (2017) Neurotrophin signaling and stem cells\u2014implications for neurodegenerative diseases and stem cell therapy. Mol Neurobiol 54:7401\u20137459","journal-title":"Mol Neurobiol"},{"key":"1940_CR9","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.biopha.2018.06.162","volume":"106","author":"X Jiang","year":"2018","unstructured":"Jiang X, Ganesan P, Rengarajan T, Choi DK, Arulselvan P (2018) Cellular phenotypes as inflammatory mediators in Parkinson\u2019s disease: Interventional targets and role of natural products. Biomed Pharmacother 106:1052\u20131062","journal-title":"Biomed Pharmacother"},{"key":"1940_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jnutbio.2015.10.013","volume":"28","author":"HD Kim","year":"2016","unstructured":"Kim HD, Jeong KH, Jung UJ, Kim SR (2016) Naringin treatment induces neuroprotective effects in a mouse model of Parkinson\u2019s disease in vivo, but not enough to restore the lesioned dopaminergic system. J Nutr Biochem 28:140\u2013146. https:\/\/doi.org\/10.1016\/j.jnutbio.2015.10.013","journal-title":"J Nutr Biochem"},{"key":"1940_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3109\/00207454.2014.982795","volume":"125","author":"S Vivekanantham","year":"2015","unstructured":"Vivekanantham S, Shah S, Dewji R, Dewji A, Khatri C, Ologunde R (2015) Neuroinflammation in Parkinson\u2019s disease: role in neurodegeneration and tissue repair. Int J Neurosci 125:717\u2013725","journal-title":"Int J Neurosci"},{"key":"1940_CR12","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/j.1742-4658.2012.08491.x","volume":"279","author":"F Blandini","year":"2012","unstructured":"Blandini F, Armentero MT (2012) Animal models of Parkinson\u2019s disease. FEBS J 279:1156\u20131166","journal-title":"FEBS J"},{"key":"1940_CR13","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.pnpbp.2010.06.004","volume":"34","author":"RM Santiago","year":"2010","unstructured":"Santiago RM, Barbieiro J, Lima MM et al (2010) Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuro-Psychopharmacol Biol Psychiatry 34:1104\u20131114","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"1940_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.nrl.2015.06.011","volume":"32","author":"D Hernandez-Baltazar","year":"2017","unstructured":"Hernandez-Baltazar D, Zavala-Flores LM, Villanueva-Olivo A (2017) The 6-hydroxydopamine model and Parkinsonian pathophysiology: Novel findings in an older model. Neurologia 32:533\u2013539","journal-title":"Neurologia"},{"key":"1940_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1006\/neur.1995.0016","volume":"4","author":"BS Jeon","year":"1995","unstructured":"Jeon BS, Jackson-Lewis V, Burke RE (1995) 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration 4:131\u2013137","journal-title":"Neurodegeneration"},{"key":"1940_CR16","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s12031-013-9984-9","volume":"50","author":"N Lev","year":"2013","unstructured":"Lev N, Barhum Y, Ben-Zur T, Melamed E, Steiner I, Offen D (2013) Knocking out DJ-1 attenuates astrocytes neuroprotection against 6-hydroxydopamine toxicity. J Mol Neurosci 50:542\u2013550. https:\/\/doi.org\/10.1007\/s12031-013-9984-9","journal-title":"J Mol Neurosci"},{"key":"1940_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0014-2999(68)90164-7","volume":"5","author":"U Ungerstedt","year":"1968","unstructured":"Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107\u2013110. https:\/\/doi.org\/10.1016\/0014-2999(68)90164-7","journal-title":"Eur J Pharmacol"},{"key":"1940_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/FBP.0000000000000441","volume":"30","author":"A Hamadjida","year":"2019","unstructured":"Hamadjida A, Frouni I, Kwan C, Huot P (2019) Classic animal models of Parkinson's disease: A historical perspective. Behav Pharmacol 30:291\u2013310","journal-title":"Behav Pharmacol"},{"key":"1940_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.biopha.2018.12.101","volume":"111","author":"SH Tan","year":"2019","unstructured":"Tan SH, Karri V, Tay NWR, Chang KH, Ah HY, Ng PQ, Ho HS, Keh HW et al (2019) Emerging pathways to neurodegeneration: dissecting the critical molecular mechanisms in Alzheimer\u2019s disease, Parkinson\u2019s disease. Biomed Pharmacother 111:765\u2013777","journal-title":"Biomed Pharmacother"},{"key":"1940_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ana.24011","volume":"74","author":"CW Olanow","year":"2013","unstructured":"Olanow CW, Schapira AHV (2013) Therapeutic prospects for Parkinson disease. Ann Neurol 74:337\u2013347. https:\/\/doi.org\/10.1002\/ana.24011","journal-title":"Ann Neurol"},{"key":"1940_CR21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/ptr.1074","volume":"15","author":"A Garg","year":"2001","unstructured":"Garg A, Garg S, Zaneveld LJD, Singla AK (2001) Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phyther Res 15:655\u2013669","journal-title":"Phyther Res"},{"key":"1940_CR22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ejphar.2016.07.042","volume":"789","author":"MS Antunes","year":"2016","unstructured":"Antunes MS, Jesse CR, Ruff JR, de Oliveira Espinosa D, Gomes NS, Altvater EET, Donato F, Giacomeli R et al (2016) Hesperidin reverses cognitive and depressive disturbances induced by olfactory bulbectomy in mice by modulating hippocampal neurotrophins and cytokine levels and acetylcholinesterase activity. Eur J Pharmacol 789:411\u2013420. https:\/\/doi.org\/10.1016\/j.ejphar.2016.07.042","journal-title":"Eur J Pharmacol"},{"key":"1940_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.brainresbull.2014.03.004","volume":"104","author":"F Donato","year":"2014","unstructured":"Donato F, de Gomes MG, Goes ATR, Filho CB, del Fabbro L, Antunes MS, Souza LC, Boeira SP et al (2014) Hesperidin exerts antidepressant-like effects in acute and chronic treatments in mice: possible role of l-arginine-NO-cGMP pathway and BDNF levels. Brain Res Bull 104:19\u201326. https:\/\/doi.org\/10.1016\/j.brainresbull.2014.03.004","journal-title":"Brain Res Bull"},{"key":"1940_CR24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S1734-1140(10)70321-2","volume":"62","author":"V Gaur","year":"2010","unstructured":"Gaur V, Kumar A (2010) Hesperidin pre-treatment attenuates NO-mediated cerebral ischemic reperfusion injury and memory dysfunction. Pharmacol Rep 62:635\u2013648. https:\/\/doi.org\/10.1016\/S1734-1140(10)70321-2","journal-title":"Pharmacol Rep"},{"key":"1940_CR25","doi-asserted-by":"publisher","unstructured":"kheradmand E, Hajizadeh Moghaddam A, Zare M (2018) Neuroprotective effect of hesperetin and nano-hesperetin on recognition memory impairment and the elevated oxygen stress in rat model of Alzheimer\u2019s disease. Biomed Pharmacother 97:1096\u20131101. https:\/\/doi.org\/10.1016\/j.biopha.2017.11.047","DOI":"10.1016\/j.biopha.2017.11.047"},{"key":"1940_CR26","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.nut.2014.03.024","volume":"30","author":"MS Antunes","year":"2014","unstructured":"Antunes MS, Goes ATR, Boeira SP, Prigol M, Jesse CR (2014) Protective effect of hesperidin in a model of Parkinson\u2019s disease induced by 6-hydroxydopamine in aged mice. Nutrition 30:1415\u20131422. https:\/\/doi.org\/10.1016\/j.nut.2014.03.024","journal-title":"Nutrition"},{"key":"1940_CR27","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/j.1471-4159.2011.07284.x","volume":"117","author":"T Carlsson","year":"2011","unstructured":"Carlsson T, Schindler FR, H\u00f6llerhage M, Depboylu C, Arias-Carri\u00f3n O, Schnurrbusch S, R\u00f6sler TW, Wozny W et al (2011) Systemic administration of neuregulin-1\u03b21 protects dopaminergic neurons in a mouse model of Parkinson\u2019s disease. J Neurochem 117:1066\u20131074. https:\/\/doi.org\/10.1111\/j.1471-4159.2011.07284.x","journal-title":"J Neurochem"},{"key":"1940_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","volume":"367","author":"U Ungerstedt","year":"1971","unstructured":"Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand 367:69\u201393","journal-title":"Acta Physiol Scand"},{"key":"1940_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0014-2999(03)01272-X","volume":"463","author":"L Prut","year":"2003","unstructured":"Prut L, Belzung C (2003) The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463:3\u201333","journal-title":"Eur J Pharmacol"},{"key":"1940_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0165-0270(85)90031-7","volume":"14","author":"S Pellow","year":"1985","unstructured":"Pellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149\u2013167. https:\/\/doi.org\/10.1016\/0165-0270(85)90031-7","journal-title":"J Neurosci Methods"},{"key":"1940_CR31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbr.2005.07.018","volume":"166","author":"F Cl\u00e9net","year":"2006","unstructured":"Cl\u00e9net F, Bouyon E, Hasco\u00ebt M, Bourin M (2006) Light\/dark cycle manipulation influences mice behaviour in the elevated plus maze. Behav Brain Res 166:140\u2013149. https:\/\/doi.org\/10.1016\/j.bbr.2005.07.018","journal-title":"Behav Brain Res"},{"key":"1940_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejphar.2005.03.029","volume":"514","author":"I Yalcin","year":"2005","unstructured":"Yalcin I, Aksu F, Belzung C (2005) Effects of desipramine and tramadol in a chronic mild stress model in mice are altered by yohimbine but not by pindolol. Eur J Pharmacol 514:165\u2013174. https:\/\/doi.org\/10.1016\/j.ejphar.2005.03.029","journal-title":"Eur J Pharmacol"},{"key":"1940_CR33","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1152\/japplphysiol.01440.2009","volume":"108","author":"AC D\u2019Audiffret","year":"2010","unstructured":"D\u2019Audiffret AC, Frisbee SJ, Stapleton PA et al (2010) Depressive behavior and vascular dysfunction: a link between clinical depression and vascular disease? J Appl Physiol 108:1041\u20131051. https:\/\/doi.org\/10.1152\/japplphysiol.01440.2009","journal-title":"J Appl Physiol"},{"key":"1940_CR34","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248\u2013254. https:\/\/doi.org\/10.1016\/0003-2697(76)90527-3","journal-title":"Anal Biochem"},{"key":"1940_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11064-015-1709-8","volume":"41","author":"AS Aguiar Jr","year":"2016","unstructured":"Aguiar AS Jr, Duzzioni M, Remor AP, Trist\u00e3o FSM, Matheus FC, Raisman-Vozari R, Latini A, Prediger RD (2016) Moderate-intensity physical exercise protects against experimental 6-hydroxydopamine-induced Hemiparkinsonism through Nrf2-antioxidant response element pathway. Neurochem Res 41:64\u201372","journal-title":"Neurochem Res"},{"key":"1940_CR36","volume-title":"The mouse brain in stereotaxic coordinates","author":"K Franklin","year":"1997","unstructured":"Franklin K, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic Press, New York"},{"key":"1940_CR37","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/(SICI)1096-9861(19960318)366:4<580::AID-CNE3>3.0.CO;2-0","volume":"366","author":"DE Oorschot","year":"1996","unstructured":"Oorschot DE (1996) Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods. J Comp Neurol 366:580\u2013599","journal-title":"J Comp Neurol"},{"key":"1940_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2015.03.018","volume":"295","author":"E Filichia","year":"2015","unstructured":"Filichia E, Shen H, Zhou X, Qi X, Jin K, Greig N, Hoffer B, Luo Y (2015) Forebrain neuronal specific ablation of p53 gene provides protection in a cortical ischemic stroke model. Neuroscience 295:1\u201310. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.03.018","journal-title":"Neuroscience"},{"key":"1940_CR39","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/j.1699-0463.1988.tb00954.x","volume":"96","author":"HJG Gundersen","year":"1988","unstructured":"Gundersen HJG, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N, M\u00d8Ller A, Nielsen K et al (1988) The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. Apmis 96:857\u2013881. https:\/\/doi.org\/10.1111\/j.1699-0463.1988.tb00954.x","journal-title":"Apmis"},{"key":"1940_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1046\/j.1365-2818.2002.01054.x","volume":"207","author":"HJG Gundersen","year":"2002","unstructured":"Gundersen HJG (2002) The smooth fractionator. J Microsc 207:191\u2013210. https:\/\/doi.org\/10.1046\/j.1365-2818.2002.01054.x","journal-title":"J Microsc"},{"key":"1940_CR41","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.neuroscience.2004.08.050","volume":"130","author":"C Schmitz","year":"2005","unstructured":"Schmitz C, Hof PR (2005) Design-based stereology in neuroscience. Neuroscience 130:813\u2013831","journal-title":"Neuroscience"},{"key":"1940_CR42","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s11055-018-0609-1","volume":"48","author":"GN Akhmadeeva","year":"2018","unstructured":"Akhmadeeva GN, Magzhanov RV, Tayupova GN, Baitimerov AR, Khidiyatova IM (2018) Depression and anxiety in Parkinson\u2019s disease. Neurosci Behav Physiol 48:636\u2013640. https:\/\/doi.org\/10.1007\/s11055-018-0609-1","journal-title":"Neurosci Behav Physiol"},{"key":"1940_CR43","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/mds.23462","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR (2011) The impact of non-motor symptoms on health-related quality of life of patients with Parkinson\u2019s disease. Mov Disord 26:399\u2013406. https:\/\/doi.org\/10.1002\/mds.23462","journal-title":"Mov Disord"},{"key":"1940_CR44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000087097","volume":"52","author":"P Willner","year":"2005","unstructured":"Willner P (2005) Chronic mild stress (CMS) revisited: Consistency and behavioural- neurobiological concordance in the effects of CMS. Neuropsychobiology 52:90\u2013110","journal-title":"Neuropsychobiology"},{"key":"1940_CR45","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1016\/s1353-8020(11)70065-7","volume":"18","author":"EC Hirsch","year":"2012","unstructured":"Hirsch EC, Vyas S, Hunot S (2012) Neuroinflammation in Parkinson\u2019s disease. Parkinsonism Relat Disord 18:S210\u2013S212. https:\/\/doi.org\/10.1016\/s1353-8020(11)70065-7","journal-title":"Parkinsonism Relat Disord"},{"key":"1940_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40035-015-0042-0","volume":"4","author":"Q Wang","year":"2015","unstructured":"Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl Neurodegener 4:19","journal-title":"Transl Neurodegener"},{"key":"1940_CR47","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/ijms17020151","volume":"17","author":"V Machado","year":"2016","unstructured":"Machado V, Z\u00f6ller T, Attaai A, Spittau B (2016) Microglia-mediated neuroinflammation and neurotrophic factor-induced protection in the MPTP mouse model of Parkinson\u2019s disease-lessons from transgenic mice. Int J Mol Sci 17:151","journal-title":"Int J Mol Sci"},{"key":"1940_CR48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cbi.2017.10.019","volume":"279","author":"ATR Goes","year":"2018","unstructured":"Goes ATR, Jesse CR, Antunes MS, Lobo Ladd FV, Lobo Ladd AAB, Luchese C, Paroul N, Boeira SP (2018) Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson\u2019s disease: Involvement of neuroinflammation and neurotrophins. Chem Biol Interact 279:111\u2013120. https:\/\/doi.org\/10.1016\/j.cbi.2017.10.019","journal-title":"Chem Biol Interact"},{"key":"1940_CR49","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.neulet.2019.05.036","volume":"706","author":"L Del Fabbro","year":"2019","unstructured":"Del Fabbro L, Rossito Goes A, Jesse CR et al (2019) Chrysin protects against behavioral, cognitive and neurochemical alterations in a 6-hydroxydopamine model of Parkinson\u2019s disease. Neurosci Lett 706:158\u2013163. https:\/\/doi.org\/10.1016\/j.neulet.2019.05.036","journal-title":"Neurosci Lett"},{"key":"1940_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","volume":"36","author":"DK Simon","year":"2020","unstructured":"Simon DK, Tanner CM, Brundin P (2020) Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 36:1\u201312","journal-title":"Clin Geriatr Med"},{"key":"1940_CR51","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/ptr.5256","volume":"29","author":"H Parhiz","year":"2015","unstructured":"Parhiz H, Roohbakhsh A, Soltani F, Rezaee R, Iranshahi M (2015) Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental models. Phyther Res 29:323\u2013331","journal-title":"Phyther Res"},{"key":"1940_CR52","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/molecules24030648","volume":"24","author":"M Hajialyani","year":"2019","unstructured":"Hajialyani M, Farzaei MH, Echeverr\u00eda J et al (2019) Hesperidin as a neuroprotective agent: a review of animal and clinical evidence. Molecules 24:648","journal-title":"Molecules"},{"key":"1940_CR53","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.tins.2010.11.001","volume":"34","author":"L Aron","year":"2011","unstructured":"Aron L, Klein R (2011) Repairing the Parkinsonian brain with neurotrophic factors. Trends Neurosci 34:88\u2013100","journal-title":"Trends Neurosci"},{"key":"1940_CR54","doi-asserted-by":"publisher","first-page":"268","DOI":"10.2174\/1570159x16666180905094123","volume":"17","author":"YA Sidorova","year":"2018","unstructured":"Sidorova YA, Volcho KP, Salakhutdinov NF (2018) Neuroregeneration in Parkinson\u2019s disease: From proteins to small molecules. Curr Neuropharmacol 17:268\u2013287. https:\/\/doi.org\/10.2174\/1570159x16666180905094123","journal-title":"Curr Neuropharmacol"},{"key":"1940_CR55","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.brainresbull.2016.03.016","volume":"124","author":"CF Li","year":"2016","unstructured":"Li CF, Chen SM, Chen XM, Mu RH, Wang SS, Geng D, Liu Q, Yi LT (2016) ERK-dependent brain-derived neurotrophic factor regulation by hesperidin in mice exposed to chronic mild stress. Brain Res Bull 124:40\u201347. https:\/\/doi.org\/10.1016\/j.brainresbull.2016.03.016","journal-title":"Brain Res Bull"},{"key":"1940_CR56","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1523\/jneurosci.14-01-00335.1994","volume":"14","author":"C Hyman","year":"1994","unstructured":"Hyman C, Juhasz M, Jackson C, Wright P, Ip NY, Lindsay RM (1994) Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT- 4\/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. J Neurosci 14:335\u2013347. https:\/\/doi.org\/10.1523\/jneurosci.14-01-00335.1994","journal-title":"J Neurosci"},{"key":"1940_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/096368970000900107","volume":"9","author":"M Espejo","year":"2000","unstructured":"Espejo M, Cutillas B, Arenas E, Ambrosio S (2000) Increased survival of dopaminergic neurons in striatal grafts of fetal ventral mesencephalic cells exposed to neurotrophin-3 or glial cell line- derived neurotrophic factor. Cell Transplant 9:45\u201353. https:\/\/doi.org\/10.1177\/096368970000900107","journal-title":"Cell Transplant"},{"key":"1940_CR58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF02816113","volume":"9","author":"EC Hirsch","year":"1994","unstructured":"Hirsch EC (1994) Biochemistry of Parkinson\u2019s disease with special reference to the dopaminergic systems. Mol Neurobiol 9:135\u2013142. https:\/\/doi.org\/10.1007\/BF02816113","journal-title":"Mol Neurobiol"},{"key":"1940_CR59","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/BF02741387","volume":"16","author":"J Haavik","year":"1998","unstructured":"Haavik J, Toska K (1998) Tyrosine hydroxylase and Parkinson\u2019s disease. Mol Neurobiol 16:285\u2013309. https:\/\/doi.org\/10.1007\/BF02741387","journal-title":"Mol Neurobiol"},{"key":"1940_CR60","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jns.2014.03.028","volume":"340","author":"EA Kozina","year":"2014","unstructured":"Kozina EA, Khakimova GR, Khaindrava VG, Kucheryanu VG, Vorobyeva NE, Krasnov AN, Georgieva SG, Kerkerian-le Goff L et al (2014) Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism. J Neurol Sci 340:198\u2013207. https:\/\/doi.org\/10.1016\/j.jns.2014.03.028","journal-title":"J Neurol Sci"},{"key":"1940_CR61","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","volume":"8","author":"KR Chaudhuri","year":"2009","unstructured":"Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson\u2019s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:464\u2013474","journal-title":"Lancet Neurol"},{"key":"1940_CR62","doi-asserted-by":"publisher","unstructured":"Draoui A, El Hiba O, Aimrane A, El Khiat A, Gamrani H (2020) Parkinson's disease: from bench to bedside. Rev Neurol (Paris). https:\/\/doi.org\/10.1016\/j.neurol.2019.11.002","DOI":"10.1016\/j.neurol.2019.11.002"},{"key":"1940_CR63","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/s-2007-1014317","volume":"27","author":"A Heinz","year":"1994","unstructured":"Heinz A, Schmidt LG, Reischies FM (1994) Anhedonia in schizophrenic, depressed, or alcohol-dependent patients\u2013neurobiological correlates. Pharmacopsychiatry 27:7\u201310","journal-title":"Pharmacopsychiatry"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-01940-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-020-01940-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-01940-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T19:41:22Z","timestamp":1621971682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-020-01940-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1940"],"URL":"https:\/\/doi.org\/10.1007\/s12035-020-01940-3","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"22 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. Specifically, all experiments in the present study were approved by Ethical Committee for Animal Use (CEUA protocol No. 001\/2013) of the Federal University of Pampa, Brazil.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}